Q&A With Alchemab CEO Young Kwon in Drug Target Review

Alchemab CEO Young Kwon and Taylor Mixides from Drug Target Review discuss how Alchemab’s research has significant potential to transform the landscape of neurodegenerative disease research and improve the lives of those affected by these challenging conditions.

@media (min-width:1042px){ #menu-primary-nav .sub-menu{ transition:transform 233ms 610ms, opacity 89ms calc(233ms + 610ms - 89ms) linear; } } @media (max-width:1041px){ #primary-navigation .menu-primary-nav-container{ -webkit-transition: -webkit-transform .233s ease-out, opacity .233s linear; transition: transform .233s ease-out, opacity .233s linear; } }